Presented at the Dutch Antisense Therapeutics Symposium (DATS) on June 1, 2023 by Monica Aguila - ProQR Therapeutics
Exploring the potential of new RNA editing technologies leveraging ADAR endogenous machinery
Presentation
Published on at DATS
Link DownloadDescription
Axiomer platform uses editing oligonucleotides (EONs) to target specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). The therapeutic possibilities of this editing platform are not only limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations with the potential to prevent diseases.
